Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis

Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Here we study associations between anti-drug antibody (ADA) occurrence and demographic and clinical factors. Retrospective data from routine ADA test laboratories in Swed...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachelet, Delphine, Hässler, Signe, Mbogning, Cyprien, Link, Jenny, Ryner, Malin, Ramanujam, Ryan, Auer, Michael, Hyldgaard Jensen, Poul Erik, Koch-Henriksen, Nils, Warnke, Clemens, Ingenhoven, Kathleen, Buck, Dorothea, Grummel, Verena, Lawton, Andy, Donnellan, Naoimh, Hincelin-Mery, Agnès, Sikkema, Dan, Pallardy, Marc, Kieseier, Bernd, Hemmer, Bernard, Hartung, Hans Peter, Soelberg Sorensen, Per, Deisenhammer, Florian, Dönnes, Pierre, Davidson, Julie, Fogdell-Hahn, Anna, Broët, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091903/
https://www.ncbi.nlm.nih.gov/pubmed/27806057
http://dx.doi.org/10.1371/journal.pone.0162752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091903/
https://www.ncbi.nlm.nih.gov/pubmed/27806057
http://dx.doi.org/10.1371/journal.pone.0162752

Ejemplares similares